The findings suggest the market has progressed beyond the initial launch period for subcutaneous PD-1 therapies. Across major tumor types, physicians project continued migration toward subcutaneous ...

Merck MRK announced that the FDA has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and its subcutaneous ...

Subcutaneous Keytruda plus chemotherapy met pharmacokinetic endpoints, showing noninferiority to the intravenous formulation in metastatic NSCLC treatment. The subcutaneous formulation, administered ...

Merck MRK announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab). This version, which will be marketed as ...

Keytruda Qlex, a subcutaneous formulation, is FDA-approved for solid tumors in patients 12 and older, offering an alternative to intravenous administration. Study MK-3475A-D77 showed comparable ...

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The forever more popular combination of Padcev and Keytruda has expanded its ...

Merck’s MRK blockbuster PD-1 inhibitor, Keytruda, approved for several types of cancer, is its key top-line driver, ...

Positive opinion also granted for KEYTRUDA as part of a perioperative regimen for the treatment of certain adult patients with resectable locally advanced head and neck squamous cell carcinoma ...

Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. Health Canada has approved Keytruda ...

In late June 2026, Merck reported multiple oncology milestones, including U.S. FDA approval of KEYTRUDA and KEYTRUDA QLEX plus Trodelvy for first-line PD-L1–positive advanced triple-negative breast ...